Biorasi was one of the first CROs in the US to manage biosimilar trials. Trust in our experience to help you navigate this growing field.
Global Biosimilars Experts
Over the next five years, the biosimilar market can expect to see double-digit growth. Biorasi has been managing clinical trials for biosimilars since the very beginning, and are well-entrenched in the biosimilars market.
There are unique challenges and complexities in managing trials for biologics and other large-molecule therapies that sponsors and CROs with decades of experience in small molecules may find themselves running into when dealing with biosimilar trials. Biorasi has been on the leading edge of biosimilar trials since the very beginning. We have run biosimilar studies in Europe since 2006, and also conducted the first biosimilar study in the US under the Affordable Care Act guidelines, and our experience has continued to grow since then.
Biosimilars are predicted to surpass a $41.7 Billion market by 2024. With so much at stake, it pays to put your trust in an industry leader with a history of specialized experience. Trust Biorasi to manage your biosimilar clinical trial from inception to approval.
"One of the rarest events, where we had to communicate [to Biorasi] to stop the screening rather than boost it."VP of Global Clinical Development, Top Specialty Pharma
Latest News and Blogs
In this blog post, we will try to understand Virtual Clinical Trial. As technology continues to become better and more integrated into the clinical development industry we are seeing increasing interest in trials that don’t require sites. Instead, many sponsors are...
Biorasi will be attending and exhibiting at the AAD 2019 Annual Meeting from March 1-5 in Washington, DC. We would like to extend a cordial invitation to all of our partners, sponsors, and friends to come visit us at booth number 2455. We will be showcasing how...